



## ReShape Lifesciences® to Present at the Q2 Virtual Investor Summit

March 15, 2023

SAN CLEMENTE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- [ReShape Lifesciences Inc. \(Nasdaq: RSLS\)](#), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive Officer, and Tom Stankovich, Chief Financial Officer, will present a company overview at the Q2 Virtual Investor Summit on Wednesday, March 29 at 1:00 pm ET. During the virtual presentation, management will highlight the Company's three pillars for growth and its portfolio of products that address the entire weight loss continuum including the anatomy-sparing Lap-Band®.

ReShape Lifesciences' management team will be available for one-on-one meetings during the Investor Summit. The conference is complimentary to qualified investors. Please register through the [Complimentary Investor Registration](#). To schedule a meeting with management outside of the conference, contact Michael Miller with Rx Communications at [mmiller@rxir.com](mailto:mmiller@rxir.com).

A live webcast of the Investor Summit presentation will be available on the "Events and Presentations" section of ReShape's website at: <https://ir.reshapelifesciences.com/events-and-presentations>. An archived replay will be available on the company's website for a period of 90 days after the conference.

### About ReShape Lifesciences Inc.

ReShape Lifesciences® is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The proprietary, FDA-approved, Lap-Band® Program provides minimally invasive, long-term treatment of obesity and is an alternative to more invasive surgical stapling procedures such as the gastric bypass or sleeve gastrectomy. ReShapeCare™ is a virtual weight-management program that supports lifestyle changes for all weight loss patients led by board-certified health coaches to help them keep the weight off over time. The recently launched ReShape Marketplace™ is an online collection of quality wellness products curated for all consumers to help them achieve their health goals. The investigational Diabetes Bloc-Stim Neuromodulation™ (DBSN™) system utilizes a proprietary vagus nerve block and stimulation technology platform for the treatment of Type 2 diabetes and metabolic disorders. The patented, Obalon® balloon technology is a non-surgical, swallowable, gas-filled intra-gastric balloon that is designed to provide long-lasting weight loss. For more information, please visit [www.reshapelifesciences.com](http://www.reshapelifesciences.com).

### CONTACTS

#### ReShape Lifesciences Investor Contact:

Thomas Stankovich  
Chief Financial Officer  
949-276-6042  
[ir@ReShapeLifesci.com](mailto:ir@ReShapeLifesci.com)

#### Investor Relations Contact:

Rx Communications Group  
Michael Miller  
(917)-633-6086  
[mmiller@rxir.com](mailto:mmiller@rxir.com)



Source: ReShape Lifesciences Inc